Full text is available at the source.
Abstract
An examination of glucagon-like peptide-1 (GLP-1) receptor agonists may reveal an association with the risk of hair loss in adults with type 2 diabetes.
- GLP-1 receptor agonists are being compared to sodium-glucose cotransporter-2 (SGLT-2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors.
- The focus is on adults with type 2 diabetes and their risk of developing alopecia.
- The study aims to clarify the potential link between these medications and hair loss.
Simplified